4D Molecular Therapeutics (FDMT) Share-based Compensation (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Share-based Compensation data on file, last reported at $4.5 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $4.5 million, down 36.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.5 million (down 28.18% YoY), and the FY2025 annual result was $22.0 million, down 15.7% from the prior year.
• Share-based Compensation slipped to $4.5 million in Q1 2026 per FDMT's latest filing, from $5.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $7.6 million in Q4 2024 and troughed at $3.9 million in Q1 2022.
• A 5-year average of $5.3 million and a median of $5.0 million in 2025 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation jumped 68.87% in 2022, then plunged 36.26% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $4.3 million in 2022, then surged by 36.06% to $5.9 million in 2023, then climbed by 28.16% to $7.6 million in 2024, then decreased by 26.72% to $5.6 million in 2025, then dropped by 19.81% to $4.5 million in 2026.
• Business Quant data shows FDMT's Share-based Compensation at $4.5 million in Q1 2026, $5.6 million in Q4 2025, and $4.5 million in Q3 2025.